Sugi Predict

Sugi Predict / Compounds / SCHEMBL5489293

SCHEMBL5489293

SCHEMBL5489293

COc1cc2c(cc1OC)C(c1ccc3ccccc3c1)=NN(C)C(=O)C2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK10 P53779 2/20 0.48
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ PTGER3 P43115 1/20 0.42
▸ ABCC1 P33527 3/20 0.41
▸ ABCB1 P08183 3/20 0.41
▸ ACHE P22303 1/20 0.40
▸ BACE1 P56817 1/20 0.40
▸ LMNA P02545 2/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ RAC1 P63000 2/20 0.39
▸ HPGD P15428 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ CASP1 P29466 1/20 0.38
▸ KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5490244 0.85 CYP1A2 (0.46) MAPK10CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL5492316 0.85 ALDH1A1 (0.53) MAPK10CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL5490848 0.83 CYP1A2 (0.44) MAPK10CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL5484921 0.82 CYP1A2 (0.50) MAPK10CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL5492941 0.82 CYP1A2 (0.47) MAPK10CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL5486147 0.82 MAPK1 (0.47) MAPK10CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL29942019 0.82 CYP1A2 (0.62) MAPK10CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL5484053 0.82 CYP1A2 (0.50) MAPK10CYP1A2CYP3A4CYP2C9MAPK1
SCHEMBL5486160 0.82 MAPK1 (0.46) CYP1A2CYP3A4CYP2C9MAPK1CYP2C19
SCHEMBL5489993 0.82 CA1 (0.39) CYP1A2CYP3A4CYP2C9MAPK1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152888-A1 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof BAY CITY CAPITAL LLC 2004-08-05 — — US claimed
US-7250410-B2 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof VIA PHARMACEUTICALS, INC. (US) 2007-07-31 — — US disclosed
US-20040152888-A1 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof BAY CITY CAPITAL LLC 2004-08-05 — — US disclosed
EP-1392663-A2 CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF NEURO3D (FR) 2004-03-03 — — EP disclosed
WO-2002098865-A2 CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITORS, PREPARATION AND USES THEREOF NEURO3D (FR) 2002-12-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152888-A1 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof PDE7A, PDE3B, PDE3A MAPK10 2388/4885CYP1A2 155/4885CYP3A4 264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.